Table 1. Clinical and anthropometric characteristics of the studied subjects.

	CNS          (n. 43)	AD             (n. 70)	TP               (n. 23)	VD            (n. 17)
Age (yrs)	66.9±12.0	77.0±7.7*	68.6±8.3	79.4±6.2*
Gender Male N (%)	21 (48.8%)	26 (37.1%)	12 (52.2%)	8 (47.1%)
Aß42     (pg/ml)	657.0 (143.0-1238.0)	384.5 (113.0-877.0) *	713.0 (194.0-1006.0)	645.0 (394.0-1107.0)
T-tau (pg/ml)	178.0 (57.0-2358.0)	447.0 (117.0-2693.0) *	247.0 (90.0-774.0)	305.0 (66.0-673.0)
P-tau (pg/ml)	35.0 (6.0-81.0)	64.0 (21.0-194.0) *	48 (2.0-112.0)	44.0 (25.0-91.0)
MMSE	25.3±3.1	14.9±6.3 *	18.2±7.7 *	20.3±7.8 *
IATI	1.4 (0.3-3.1)	0.5 (0.1-1.7) *	1.1 (0.3-2.1) *	1.3 (0.5-2.2)
NF-light (pg/ml)	796.7 (81.3-1584.3)	1332.7 (424.7-5730.1) **	2071.0 (400.5-7864.9) **	1603.2 (370.1-6295.7) ++
MiR-21	324.7±215.1	369.7±236.9	304.9±139.3	286.1±177.5
MiR-125b	171.8±165.5	166.6±151.2	129.1±122.1	167.0±199.9
MiR-146a	14.8±15.1	14.4±11.2	16.5±19.5	16.4±18.9
MiR-222	11.2±12.1	13.8±13.8	23. ±58.8	40.6±64.0++

Data are reported as mean ± SD or as median (Interquartile Range) as appropriate. Aß42: beta-amyloid (1-42) peptide. T-tau: Tau protein. P-tau: threonine-181 hyperphosphorylated tau protein. MMSE: Mini Mental State Evaluation. IATI: Innotest Amyloid Tau Index. CNS: cognitively normal subjects. AD: Alzheimer’s diseases. TP: the TP group was composed of 3 patients with progressive supranuclear palsy (PSP), 19 patients with frontotemporal dementia (FTD) and 3 patients with corticobasal degeneration (CBD). VD: vascular dementia. *p<0.05 vs. CNS group; ⁺⁺ p<0.01 vs. CNS and AD group; ** p< 0.01 vs. CNS.